Equities

Regenxbio Inc

Regenxbio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.93
  • Today's Change-0.57 / -4.56%
  • Shares traded184.79k
  • 1 Year change-32.10%
  • Beta1.2182
Data delayed at least 15 minutes, as of Sep 20 2024 16:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy4
Outperform7
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 12 analysts offering 12 month price targets for Regenxbio Inc have a median target of 39.00, with a high estimate of 52.00 and a low estimate of 21.00. The median estimate represents a 212.00% increase from the last price of 12.50.
High316.0%52.00
Med212.0%39.00
Low68.0%21.00

Earnings history & estimates in USD

On Aug 01, 2024, Regenxbio Inc reported 2nd quarter 2024 losses of -1.05 per share. This result exceeded the -1.29 consensus loss of the 8 analysts covering the company and exceeded last year's 2nd quarter results by 36.75%.
The next earnings announcement is expected on Nov 06, 2024.
Average growth rate+10.26%
Regenxbio Inc reported annual 2023 losses of -6.02 per share on Feb 27, 2024.
Average growth rate-4.06%
More ▼

Revenue history & estimates in USD

REGENXBIO Inc. had 2nd quarter 2024 revenues of 22.30m. This missed the 22.97m consensus estimate of the 7 analysts following the company. This was 16.50% above the prior year's 2nd quarter results.
Average growth rate+8.65%
REGENXBIO Inc. had revenues for the full year 2023 of 90.24m. This was 19.94% below the prior year's results.
Average growth rate+111.76%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.